In contrast, loss of Cdh1 was recently shown to bypass the dependency of cancer cells on Cdk4/6 [77], indicating that Cdh1 loss may constitute an exclusion criterion for treatment with the recently developed Cdk4/6 inhibitors, or could be a mechanism of acquired resistance to such drugs. Here, CDK4 is linked to cancer.